# Independent clinical specification review

**Review date:** November 9, 2026 UTC. **Reviewer:** `/root/diagnostic_evidence`. **Review class:** independent AI document walkthrough and limited static code inspection. This is not qualified clinical approval, a patient study, a live product test or a clinical rehearsal.

## Recommendation

**The corrected protocol is suitable for continued local clinical and methods review and preparation of an unsigned acceptance packet. It is not a frozen clinical study specification or an accepted clinical pathway.** All ten tabletop cases state appropriate document boundaries for the proposed scope. They are ten synthetic scenarios reviewed on paper, not ten executed clinical cases or a measured safety rate.

Three substantive issues were initially identified and corrected by the integration owner during this review: conflicting primary-endpoint definitions, conflation of action-occurrence verification with independent clinical appropriateness adjudication, and an unspecified origin for the ACS follow-up benchmark. A second correction added explicit episode/action/question identity and closure, separated eligibility knowability from assessment, and separated transfer from an endpoint-precluding competing event. I independently inspected both sets of changed text and retained the earlier findings and exact source hashes. These six document corrections are verified; no clinical effect or clinical acceptance follows.

The remaining local inputs are material and are correctly unfilled: accepted clinical and operational roles, participating site, full applicable guidance review, capacity, resources, ethics/privacy determinations, a locked estimand and analysis plan, validated function instrument, actual end-to-end rehearsal and independent human evaluation. No null clinical observation is recoded as zero.

## Exact review scope

The review covers the protocol v0.2, the acceptance JSON, event dictionary CSV and ten-scenario tabletop JSON, plus static inspection of `apps/dis-platform/lib/research-workflow.ts`. The initial repository HEAD was `1969e2e7af73f8ba65ab48fe1e761a1a9f4222b0`; the clinical files were modified or untracked, so the reviewed candidate is identified by file hashes rather than falsely attributed to that commit. Initial snapshots are in `reviewed_sources/`; corrected snapshots and final hashes are recorded separately in the review receipts.

### Final reviewed file hashes

| File | SHA-256 |
|---|---|
| EARLY-RECOGNITION-ACTION-AND-DIAGNOSTIC-CLOSURE-PROTOCOL-2026-11-07.md | `dccc6c36f5713810b312af6b2e857c43765449af2aac2ff18a68d5d4441b444d` |
| clinical_pathway_acceptance.json | `b031c35ec11178b0a7dbeb8b3244d9d28f78f72a459b4e1be2dbb1f6b5df0b44` |
| clinical_pathway_event_dictionary.csv | `32f89aac6f6f4b290997bf46f934d0c6b48ff946db84438d10a5bfbf565cd410` |
| clinical_pathway_tabletop.json | `4344fd8a2104e1743a98a05d22b077bea258114c2321f0c84f2030e72b1ae3f6` |
| research-workflow.ts | `4c622ef4e5480eb438634ae15ba7d9ab2cd43106742e88df83a9471c1ac50d7f` |

No source file in the integration repository was changed by this reviewer. The prior denominator evidence snapshots were not changed. No clinical records, external messages, paid agents or patient encounters were involved.

## 1. Before, changed, proof and remaining limits

| Finding | Original problem | Verified correction | Remaining acceptance boundary |
|---|---|---|---|
| CSR01 — primary endpoint | The earlier endpoint section allowed appropriate action and/or function; Phase C specified appropriate completed action. This permitted different interpretations of success. | Both sections now specify time from a locked track-specific eligible index event to independently verified appropriate completed action. Completion by a horizon and patient function are secondary. | Each track still needs a locally accepted action definition, time origin, horizon, analysis unit and estimand before enrollment. |
| CSR02 — independent appropriateness | `completion_verified_at` allowed independent or authorized verification without a separate structured clinical appropriateness judgment. An administrative completion check could be mistaken for the primary endpoint. | Completion evidence and qualified independent appropriateness adjudication are separate. The dictionary now carries reviewer, rubric, decision, adjudication time and disagreement fields; the narrative requires both components. | CP04 must define adjudicator independence, conflicts, masking where feasible and disagreement resolution. If an independence exception is necessary, it must be reported explicitly rather than silently counted as independent verification. |
| CSR03 — guideline clock | The preferred ACS interval was stated without an explicit starting event, alongside several possible process clocks. | The guideline benchmark is now anchored to the initial test and distinguished from result availability to the responsible team. | Operational definitions must retain those clocks, plus enrollment and capture time, without reset. Source-processing delay and response delay are different quantities. |
| CSR04 — identity and closure | The dictionary lacked stable action/episode/question linkage and offered a single closure scope despite parallel clinical questions. | Stable episode, action and diagnostic-question identifiers and separate action/question/episode closure statuses are now explicit. | Authorized implementation and rehearsal must demonstrate that a completed action cannot overwrite another open question or episode. |
| CSR05 — eligibility clocks | `eligibility_assessed_at` originally described when eligibility became assessable, conflating availability with actual assessment. | Separate `eligibility_knowable_at` and `eligibility_assessed_at` fields now distinguish the events. | Local time-zero definitions must specify evidence availability, precision and missingness; naming the fields alone does not authenticate timestamps. |
| CSR06 — transfer and ascertainment | The dictionary listed transfer as a possible competing event without separating loss of observation from prevention of the clinical endpoint. | Transfer status, endpoint-precluding events and observation-end reasons are now distinct. Narrative explicitly rejects automatic competing-event classification for transfer. | Freeze censoring, authorized reconciliation and informative-missingness sensitivity before analysis. |

These corrections are document-level safeguards. The event dictionary remains a specification, not evidence that any database, user interface or clinician workflow enforces the rules.

## 2. Individual tabletop findings

| Scenario | Independent document finding | Required interpretation and remaining check |
|---|---|---|
| **CP-T01: positive stool test, referral and repeat negative test** | Boundary is concordant with the protocol and current ACS guidance. | Evaluation remains unresolved without the indicated follow-up evidence. A repeat stool result or referral order cannot be counted as completed colonoscopy. Rehearsal must also distinguish a procedure event from adequate diagnostic evaluation, communicated results and any pending pathology/follow-up. |
| **CP-T02: symptoms below routine screening age** | Boundary correctly separates symptomatic evaluation from average-risk screening. | Retain the symptomatic track and clinician-selected urgency. The person must not disappear from an appropriate symptomatic denominator merely because they are outside screening age eligibility. This does not select a diagnostic test for the person. |
| **CP-T03: persistent pelvic symptoms with normal ultrasound** | Boundary is consistent with the official NICE recommendations and the protocol's differential/reassessment approach. | Normal imaging alone cannot terminate review of suspected endometriosis. Ongoing symptoms and function, alternative diagnoses and clinician-governed referral decisions remain observable. A completed scan is a completed action, not necessarily a resolved clinical episode. |
| **CP-T04: informed decline with requested reassessment** | Boundary preserves patient choice and avoids fabricating completion or harm. | Keep the person in the prespecified eligible cohort and record preferences, reassessment and subsequent changes of choice. Decline is not automatically a permanent competing event. The primary analysis must not improve simply by removing decliners. |
| **CP-T05: reported outside procedure with unreconciled evidence** | Boundary correctly preserves patient-reported evidence while distinguishing reported from verified completion and accepted transfer. | Receiving-team acceptance, clinical completion and data observability are separate. A transfer must not automatically become a competing event if the endpoint can still occur elsewhere. Seek only authorized reconciliation; absence of records is not proof of absent care. |
| **CP-T06: uncertain onset predating recorded care** | Boundary appropriately separates recalled onset, first observed presentation and missingness. | Retain onset intervals/uncertainty and the data-system observation boundary. Do not infer symptom-to-presentation delay from a single imputed onset or analyze only confirmed cases. The study's locked primary index may differ from a recalled symptom-onset clock. |
| **CP-T07: identifiable clinical data proposed for public casework** | The prohibition is appropriate for the stated research boundary. | This is an instruction to decline ingestion, not a witnessed privacy control. The current public-aggregate declaration in code is operator attestation, not certification that free text is free of identifiers. CP02 and CP05 require the actual approved clinical boundary and its safeguards. |
| **CP-T08: outreach grows while receiving capacity is unchanged** | Boundary addresses a credible system failure and avoids counting activity as benefit. | Record backlog, scheduling capacity, urgent access, staff/patient burden and displacement of other care. Any added capacity or staffing must be balanced or named as an intervention component. A growing queue may require adaptation without establishing clinical harm from the queue alone. |
| **CP-T09: urgent concern in a research queue** | Boundary properly preserves existing clinical triage and covering responsibility. | The research queue must not become the emergency pathway. The future authorized rehearsal must witness escalation, ownership during absence and continued ordinary care while the research-enabled action is suspended. No actual triage response was tested here. |
| **CP-T10: endometriosis narrative through CRC builder** | Document prohibition is appropriate, and the implementation restriction is real. | Static code always builds the colorectal baseline and exposes no condition discriminator. A free-text narrative does not establish a different pathway. This review does not claim that the running app detects or rejects an endometriosis narrative. Condition-specific support remains unimplemented/unaccepted; do not attach the CRC baseline or infer safety from generic casework. |

No contradictory clinical action instruction was found within these ten required-boundary statements. Their coverage is limited: they do not establish execution, recovery, adequate performance under all combinations, or patient benefit.

## 3. Estimands and denominators

The protocol's separation of screening eligibility, symptomatic evaluation and abnormal-test follow-through is necessary. They are different entry cohorts and should not be pooled into one completion percentage. For the initial CRC follow-through study, define the eligible abnormal-test population before examining action completion. For suspected endometriosis, include eligible symptomatic presentations whether ultimately diagnosed, unresolved or assigned an alternative diagnosis. Eligibility, action appropriateness and confirmed diagnosis are distinct judgments.

The chosen endpoint also needs a prespecified set of qualifying actions for each track. A rapid, low-burden first action must not automatically outrank a slower but clinically necessary action simply because both satisfy a broad label. The responsible clinical pair must define sufficiency, communication and follow-through components using the frozen rubric and patient context. A person with parallel actions needs linked records; otherwise a completed symptom-management action could accidentally close an unresolved diagnostic question.

Time-to-event inference needs the whole prespecified eligible cohort and a defined observation horizon. Reporting only the median among completers selects on the outcome. Loss of observability, transfer, decline, death and administrative end need separate definitions and an explicit analysis strategy. A change of care location does not necessarily prevent the clinical endpoint; it may instead change ascertainment. Repeated presentations and actions must have a declared episode/person/cluster unit so they are not treated as independent participants.

The proposal to measure competent existing care, staffing, capacity and contact intensity supports an interpretable comparison. It also correctly avoids assigning a package effect to navigation or DIS reasoning alone. Randomization, allocation, interference, calendar time, covariates and event handling are not yet frozen; no sample-size or causal-effect readiness follows. The separate 24-slot decision-method study supplies no clinical sample-size calculation or clinical benefit estimate.

### Corrected measurement requirements and remaining local freeze work

1. **Identity and linkage — document correction verified:** case, episode, action and question identifiers are now distinct. The future authorized implementation must link repeated/parallel actions to their own completion, adjudication and follow-up evidence.
2. **Simultaneous closure states — document correction verified:** action, diagnostic-question and episode closure fields are now separate. Future rehearsal must show that one closure does not overwrite another open state.
3. **Temporal availability — document correction verified; operational mapping pending:** eligibility knowability and assessment are now separate, and the initial-test benchmark is explicit. Retain initial test, final result, team availability, enrollment and capture clocks; locally declare how each maps to the analysis time zero.
4. **Clinical action quality:** the rubric must determine whether a procedure/evaluation was adequate, whether relevant results remain pending and what communication or follow-through completes the specified endpoint.
5. **Observation and competing events — transfer document correction verified:** the revised dictionary and narrative preserve transfer and observation end separately. Decline also must not be mechanically coded as an event that precludes later appropriate action. Preserve authorized outside care and uncertainty; prespecify the estimator and sensitivity to missing outcomes.
6. **Adjudication and patient outcomes:** retain independent judgments and exceptions; specify measurement times, instrument version/language and missingness for repeated patient-reported function. Adjudicator agreement needs uncertainty rather than a single unsupported agreement claim.

These are preparation and measurement-freeze requirements, not evidence that any enrolled patient was managed incorrectly. The final finding ledger marks the six corrected document items separately from the clinical/site/implementation evidence that has not been collected.

## 4. Clinical guidance checks and limits

I independently rechecked the current ACS publisher text, official USPSTF statement, official NICE recommendations and ACOG's official announcement/abstract identity. ACS calls for timely colonoscopy after a positive noncolonoscopy screen, preferably within six months of the initial test, and advises against repeating a positive stool/blood test before referral. This does not establish a universal safe waiting period or replace individual urgency.[1]

USPSTF 2021 concerns asymptomatic average-risk adults; it is not a rule for dismissing symptoms outside routine screening eligibility.[2] NICE NG73 preserves suspicion despite a normal examination/scan and permits investigation/referral alongside initial management, with referral for persistent symptoms or functional impact.[3]

ACOG's 2026 official announcement supports clinician-made presumptive diagnosis and appropriate empiric care during continued evaluation. The complete guideline remains access restricted in this review, and detailed local rule acceptance requires qualified review of the full applicable version. This review neither substitutes a news announcement for the complete recommendation set nor imports UK thresholds wholesale into a U.S. pathway.[4,5]

The protocol's two diagnostic-delay review statistics and full ESHRE recommendation set were not independently re-extracted in this targeted specification review. They must not be represented as newly audited here. The exact-target Google Scholar search for the ACS guideline returned a related report rather than the guideline itself; **Google Scholar verification was not achieved**. Publisher/agency verification is reported separately.

## 5. Readiness and next acceptance evidence

| Decision | Recommendation |
|---|---|
| Preserve and integrate the corrected research specification with its limitations | **Conditional GO for preparation and qualified local review** |
| Declare a frozen clinical study protocol/analysis plan | **Not established; CP04 inputs remain required** |
| Accept clinical use, enroll patients, authorize clinical data ingestion or operate an endometriosis workflow | **Not accepted by this review** |
| Count the tabletop as executed clinical rehearsal or evidence of clinical benefit | **Unsupported** |
| Continue the wider earliest-signal mission while using CRC follow-through as an initial tractable pathway | **Consistent with the stated protocol and implementation limits** |

The next concrete review should involve the actual site clinical lead and independent clinical adjudicators, with operational/data leads and patient/community participation. Their task is to reconcile complete guidance, local differential/urgency rules, capacity, the qualifying-action rubric and the measurement items above. They must accept their roles and source-bound decisions. This review supplies an auditable preparation packet; it does not sign on their behalf.

Before CP05, add a small number of discriminating rehearsal cases: an apparently completed but inadequate or result-pending evaluation; parallel actions with only one completed; and a corrected result or late receipt that must not reset the original clock. These specifically challenge unresolved semantics. They are not a demand to maximize test counts or a claim that the current ten cases form a comprehensive safety suite.

### Primary references

1. Wolf AMD, Hoffman RM, Walter LC, et al. Colorectal cancer screening: an update to the American Cancer Society guideline, 2026. *CA Cancer J Clin.* 2026;76(3):e70083. doi:[10.3322/caac.70083](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.70083). Publisher full text, recommendations/rationale and follow-up discussion inspected November 9, 2026.
2. US Preventive Services Task Force. [Colorectal cancer: screening](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening). Published May 18, 2021. Population and practice considerations inspected November 9, 2026.
3. National Institute for Health and Care Excellence. [Endometriosis: diagnosis and management. NG73](https://www.nice.org.uk/guidance/ng73/chapter/Recommendations). Updated November 11, 2024. Official indexed recommendations 1.5.1–1.5.7 inspected November 9, 2026.
4. American College of Obstetricians & Gynecologists. [ACOG publishes new endometriosis clinical guidance, aiming to shorten time to diagnosis and improve access to care](https://www.acog.org/news/news-releases/2026/02/acog-publishes-new-endometriosis-clinical-guidance-aiming-shorten-time-diagnosis-improve-access-care). Published February 20, 2026. Official indexed announcement inspected; direct open returned access restriction.
5. American College of Obstetricians & Gynecologists' Committee on Clinical Practice Guidelines–Gynecology. Diagnosis of Endometriosis. *Obstet Gynecol.* 2026;147(3):432-448. doi:[10.1097/AOG.0000000000006181](https://doi.org/10.1097/AOG.0000000000006181). [PMID 41712950](https://pubmed.ncbi.nlm.nih.gov/41712950/). Abstract/identity inspected; full guideline not accessed.

The report, exact before/after file identities, individual scenario findings and guidance-check receipt belong together. An acceptance field or automated schema check would establish neither qualified reviewer participation nor truth of a clinical claim.
